Company Encyclopedia
View More
name
CRMI
08158.HK
China Regenerative Medicine International Limited, an investment holding company, provides healthcare products and services in Hong Kong and the People’s Republic of China. The company operates through Aesthetic Medical and Beauty Services; and Medical Services segments. It offers medical beauty products and services; and medical products and services. The company was formerly known as China Bio-Med Regeneration Technology Limited and changed its name to China Regenerative Medicine International Limited in March 2015.
1.377 T
08158.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking38/52
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE4.68%C
    • Profit Margin2.18%C
    • Gross Margin65.28%A
  • Growth ScoreB
    • Revenue YoY5.75%C
    • Net Profit YoY101.28%A
    • Total Assets YoY8.84%B
    • Net Assets YoY15.63%A
  • Cash ScoreB
    • Cash Flow Margin4591.72%A
    • OCF YoY5.75%C
  • Operating ScoreC
    • Turnover0.38C
  • Debt ScoreE
    • Gearing Ratio81.59%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CRMI Reports Sufficient Internal Controls After Governance Review

    China Regenerative Medicine International Limited (CRMI) has reported that its internal control review, prompted by past non-compliance with GEM Listing Rules, has been positively assessed by an independent consultant. The consultant confirmed that CRMI's remedial measures are adequate, ensuring reliable governance and internal control systems. The Board and consultant will continue to oversee these systems for ongoing compliance.

    Reuters·
    HK
    08158
    -3.57%
    Reuters·
    HK
    08158
    -3.57%

    CRMI released its interim results, with a profit attributable to shareholders of HKD 4.609 million, a year-on-year decrease of 78.15%

    According to the Zhitong Finance APP, China Regenerative Medicine released its interim results for the six months ending June 30, 2025. The group achieved revenue of HKD 27.391 million, a year-on-year decrease of 54.18%; the profit attributable to equity holders of the company was HKD 4.609 million, a year-on-year decrease of 78.15%; earnings per share were HKD 0.0151

    Zhitong·
    HK
    08158
    -3.57%
    Zhitong·
    HK
    08158
    -3.57%

    CRMI appoints Zhou Xudong as an independent non-executive director

    According to the Zhitong Finance APP, China Regenerative Medicine announced that Liu Ming has resigned as an independent non-executive director due to personal matters and will no longer serve as the chairman of the audit committee, nomination committee, and remuneration committee, effective June 30, 2025. From the same date, Zhou Xudong has been appointed as an independent non-executive director, a member of the audit committee, and the chairman of both the remuneration committee and the nomination committee

    Zhitong·
    HK
    08158
    -3.57%
    Zhitong·
    HK
    08158
    -3.57%

    CRMI appoints Luo Min as a non-executive director

    CRMI announced that Huang Baotian resigned as Chief Financial Officer and Company Secretary due to personal matters, effective April 25, 2025. Meanwhile, Luo Min has been appointed as a non-executive director, and Yan Shibin will serve as Chief Financial Officer

    Zhitong·
    HK
    08158
    -3.57%
    Zhitong·
    HK
    08158
    -3.57%

    CRMI: Jindao Liancheng appointed as the new auditor

    According to the Zhitong Finance APP, China Regenerative Medicine announced that on January 6, 2025, Zhongzheng Tianheng Accounting Firm submitted a resignation letter to the board of directors, resigning from the position of company auditor, effective immediately. Upon the recommendation of the audit committee, Jindao Liancheng Accounting Firm Co., Ltd. has been appointed as the new auditor of the company starting from January 6, 2025, to fill the temporary vacancy left by Zhongzheng Tianheng's resignation, with a term ending at the conclusion of the company's next annual general meeting

    Zhitong·
    HK
    08158
    -3.57%
    Zhitong·
    HK
    08158
    -3.57%
    © 2025 Longbridge｜Disclaimer